IGF-1 LR3 - 1MG

Log in to view pricing Apply for provider account
IGF-1 LR3 - 1MG
Availability:
In Stock

Product Overview

IGF-1 LR3

IGF-1 LR3 (1 mg) is a long-acting analog of insulin-like growth factor-1 (IGF-1), engineered to reduce affinity for IGF-binding proteins and extend half-life, increasing bioavailability and prolonging anabolic activity compared to native IGF-1.[1][2] IGF-1 is a key mediator of skeletal muscle growth, regeneration, and repair through IGF-1R activation of the PI3K/Akt/mTOR pathway, promoting protein synthesis and inhibiting proteolysis.[3][4][5][6][7] It also activates satellite cells to drive myoblast proliferation and differentiation, essential for hypertrophy and recovery after injury.[3][4][8][7]

Preclinical data show IGF-1 LR3 and other variants are more potent than native IGF-1 in enhancing nitrogen retention, body weight, and muscle protein synthesis—especially in catabolic states.[1][2] LR3IGF-1 is reported to be ~1.5–2.5× more potent than IGF-1 in animal models, with superior effects on body weight, nitrogen balance, and reduced muscle protein breakdown, largely due to diminished binding to IGFBPs and improved tissue uptake.[1][2][9]

IGF-1 LR3 improves nutrient partitioning by directing amino acids and glucose toward muscle, supporting lean mass accrual and potentially reducing fat mass.[9][10][11] In animals, IGF-1 analogs increase lean mass and reduce adiposity (with limited preservation of muscle during caloric restriction).[10] In humans, recombinant IGF-1 increases lean body mass, decreases fat mass, and improves protein synthesis/fat oxidation in deficiency states;[11] however, randomized trials in healthy athletes have not shown clear body-composition gains, though some report improved aerobic performance (VO2max).[12][13][14]

IGF-1 LR3 supports tissue repair and accelerates recovery via satellite cell activation, myogenic differentiation, and muscle regeneration—of interest for recovery from intense exertion or musculoskeletal injury.[3][4][15][16][7]

While potent in preclinical models, IGF-1 LR3 is not approved for performance enhancement in humans, and safety at supraphysiologic doses is not fully defined. Potential risks include hypoglycemia, edema, and arthralgia, with theoretical tumorigenesis concerns under chronic exposure. IGF-1 and analogs are banned in competitive sports.[9][13][14]

Summary: IGF-1 LR3 is a long-acting IGF-1 analog with anabolic, regenerative, and nutrient-partitioning effects in preclinical studies. Human data support improvements in protein metabolism and body composition primarily in deficiency states; robust evidence for enhancement in healthy individuals is limited.[12][11][13][14]

References

  1. Tomas FM, Knowles SE, Owens PC, et al. Biochem J. 1992;282(Pt1):91-7. doi:10.1042/bj2820091.
  2. Tomas FM, Lemmey AB, Read LC, Ballard FJ. J Endocrinol. 1996;150(1):77-84. doi:10.1677/joe.0.1500077.
  3. Vassilakos G, Barton ER. Compr Physiol. 2018;9(1):413-438. doi:10.1002/cphy.c180010.
  4. Ahmad SS, Ahmad K, Lee EJ, et al. Cells. 2020;9(8):E1773. doi:10.3390/cells9081773.
  5. Philippou A, Barton ER. Growth Horm IGF Res. 2014;24(5):157-63. doi:10.1016/j.ghir.2014.06.003.
  6. Velloso CP. Br J Pharmacol. 2008;154(3):557-68. doi:10.1038/bjp.2008.153.
  7. Yoshida T, Delafontaine P. Cells. 2020;9(9):E1970. doi:10.3390/cells9091970.
  8. Duan C, Ren H, Gao S. Gen Comp Endocrinol. 2010;167(3):344-51. doi:10.1016/j.ygcen.2010.04.009.
  9. Bailes J, Soloviev M. Biomolecules. 2021;11(2):217. doi:10.3390/biom11020217.
  10. Tomas FM. Growth Horm IGF Res. 2001;11(2):92-103. doi:10.1054/ghir.2000.0194.
  11. Mauras N, Martinez V, Rini A, Guevara-Aguirre J. J Clin Endocrinol Metab. 2000;85(9):3036-42. doi:10.1210/jcem.85.9.6772.
  12. Guha N, Nevitt SP, Francis M, et al. J Clin Endocrinol Metab. 2015;100(8):3126-31. doi:10.1210/jc.2015-1996.
  13. Anderson LJ, Tamayose JM, Garcia JM. Mol Cell Endocrinol. 2018;464:65-74. doi:10.1016/j.mce.2017.06.010.
  14. Holt RI, Sönksen PH. Br J Pharmacol. 2008;154(3):542-56. doi:10.1038/bjp.2008.99.
  15. Song YH, Song JL, Delafontaine P, Godard MP. Trends Endocrinol Metab. 2013;24(6):310-9. doi:10.1016/j.tem.2013.03.004.
  16. Barton ER. Appl Physiol Nutr Metab. 2006;31(6):791-7. doi:10.1139/h06-054.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.

TruForm Labs is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. TruForm Labs is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.